Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus
- 1 January 1992
- journal article
- clinical trial
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 29 (4) , 321-322
- https://doi.org/10.1007/bf00685952
Abstract
Summary A total of 26 evaluable patients presenting with advanced or metastatic squamous-cell carcinoma of the esophagus were entered in a phase II trial to assess the single-agent activity of etoposide. Etoposide was given at a dose of 200 mg/m2 on 3 consecutive days every 3 weeks. Five patients (19%) achieved a partial response and seven (27%) experienced stabilisation of their disease. The median duration of response was 4 months (range 3–8 months). The major toxicity was leukopenia, which reached WHO grade 3 in 46% of patients and grade 4 in 11% of cases, with five instances of leukopenic fever and one therapy-associated death being recorded. Etoposide given at this dose and on this schedule seems to have considerable activity against non-pretreated metastatic esophageal carcinoma.Keywords
This publication has 7 references indexed in Scilit:
- Chemotherapy for advanced epidermoid carcinoma of the esophagus with single-agent cisplatin: final report on a Southwest Oncology Group study.1984
- Chemotherapy of esophageal cancer.1984
- Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma.1983
- Phase II study of etoposide in the treatment of esophageal carcinoma.1983
- Chemotherapy of advanced esophageal carcinoma: Eastern cooperative oncology group experienceCancer, 1980
- Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.1979
- VINDESINE IN THE TREATMENT OF ESOPHAGEAL-CARCINOMA - PHASE-II STUDY1979